Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Protollin

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
ABSTRACT Influenza A/H3N2 viruses have caused the most severe epidemics since 1968 despite current immunization programs with… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
2010
2010
Glial activation and increased inflammation characterize neuropathology in Alzheimer's disease (AD). The aim was to develop a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
BACKGROUND Immunization of mice with the G protein of respiratory syncytial virus (RSV) characteristically induces an immune… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
An intranasal vaccine composed of Toll-like receptor 2 (TLR2) ligand Neisseria meningitidis outer membrane proteins and Toll-like… Expand
2008
2008
We assessed whether peripheral activation of microglia by a nasal proteosome‐based adjuvant (Protollin) that has been given… Expand
2007
2007
The protective efficacy of an intranasal (IN) Protollin-eRSV vaccine has recently been demonstrated in the RSV-susceptible BALB/c… Expand
2007
2007
Abstract The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2006
Highly Cited
2006
F1-V is a recombinant plague antigen comprising the capsular (F1) and virulence-associated (V) proteins. Given intramuscularly… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Protollin-MV is a vaccine produced by mixing split measles virus (MV) antigen with the novel adjuvant Protollin (Neisseria… Expand
2004
2004
Protollin is a novel adjuvant comprising Proteosomes non-covalently complexed with LPS. Intranasal immunization of mice with… Expand